In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...